24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs

计划入组 61 人 · 首次发布于 2026 年 4 月 22 日

Validation of Tie2 as the First Tumour Vascular Response Biomarker for VEGF Inhibitors: VALTIVE1

计划入组 176 人 · 首次发布于 2020 年 8 月 21 日

A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes

计划入组 71 人 · 首次发布于 2011 年 12 月 21 日

BAY-Tie2

anti-VEGF/Tie2 bispecific antibody (Aerpio Pharmaceuticals)

Ang2/Tie2 interactions affibody(University of Oregon)

CARDINAL TIEN HOSPITAL

Taiwan

KUANG TIEN GENERAL HOSPITAL

Taiwan

SOUTHERN TIER HOME MEDICAL SUPPLIES, INC.

United States

Ingenia Therapeutics Receives KRX Approval for IPO as TIE2-Targeted Therapies Advance to Phase 3

PharmAbcine's PMC-403 Receives Safety Approval for 4mg Single-Dose Cohort in Phase 1 AMD Trial

Longeveron's Lomecel-B Shows Promise in Mild Alzheimer's Disease by Targeting MMP14